Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Colesevelam.

E B Melian1, G L Plosker

  • 1Adis International Inc., Langhorne, Pennsylvania, USA. demail@adis.com

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|January 20, 2004
PubMed
Summary
This summary is machine-generated.

Colesevelam effectively lowers LDL and total cholesterol in patients with hypercholesterolemia. This bile acid sequestrant is well-tolerated, with fewer gastrointestinal side effects than other treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tacrolimus ointment. A review of its therapeutic potential as a topical therapy in atopic dermatitis.

American journal of clinical dermatology·2002
Same author

Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer.

PharmacoEconomics·2002
Same author

Cisplatin/epinephrine injectable gel.

Drugs & aging·2001
Same author

Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.

PharmacoEconomics·2001
Same author

Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections.

PharmacoEconomics·2001
Same author

Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation.

Drugs·2001
Same journal

GLP-1 Receptor Agonists and Cardiovascular Outcomes in Patients with Type 2 Diabetes Across Myocardial Infarction-Defined Populations: A Systematic Review and Meta-Analysis.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
Same journal

Clinical Pharmacology of Plozasiran.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
Same journal

De-risking Atrial Fibrillation: Refining Anticoagulation Decision-Making.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
Same journal

Correction: Impact of Aspirin on Primary Prevention of Cardiovascular Events in Patients with Elevated Lipoprotein(a): A Systematic Review and Meta-analysis.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
Same journal

Comment on "Polypill Strategy: A Paradigm Shift in Cardiovascular Disease Prevention".

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
Same journal

Spironolactone or Finerenone for Cardiovascular and Kidney Protection in Patients with Moderate CKD?

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
See all related articles

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Gastroenterology

Background:

  • Colesevelam is a lipid-lowering polymer and bile acid sequestrant.
  • It is used to treat hypercholesterolemia.
  • It has a high affinity for bile acids and is not systemically absorbed.

Purpose of the Study:

  • To evaluate the efficacy and safety of colesevelam in treating primary hypercholesterolemia.
  • To assess the impact of colesevelam on lipid profiles.
  • To examine the effects of combination therapy with HMG-CoA reductase inhibitors.

Main Methods:

  • Oral administration of colesevelam to patients with primary hypercholesterolemia.
  • Assessment of serum lipid levels (LDL-cholesterol, total cholesterol) over 6 and 24 weeks.

Related Experiment Videos

  • Evaluation of combination therapy with HMG-CoA reductase inhibitors (lovastatin, simvastatin, atorvastatin).
  • Monitoring of adverse events, vitamin levels, coagulation parameters, and liver enzymes.

    • Main Results:

    • Colesevelam significantly reduced LDL-cholesterol and total cholesterol levels.
    • Lipid-lowering effects were sustained over 24 weeks.
    • Combination therapy showed additive reductions in LDL-cholesterol and total cholesterol.
    • Colesevelam was well-tolerated, with constipation and dyspepsia as the most common adverse events.
    • No clinically significant changes in vitamins, coagulation, or liver enzymes were observed.

    Conclusions:

    • Colesevelam is an effective and well-tolerated treatment for primary hypercholesterolemia.
    • It offers sustained lipid-lowering benefits.
    • Combination therapy with HMG-CoA reductase inhibitors enhances lipid reduction.
    • Colesevelam presents a favorable safety profile compared to other bile acid sequestrants.